In today’s recent session, 0.42 million shares of the Perspective Therapeutics Inc (AMEX:CATX) have been traded, and its beta is 1.23. Most recently the company’s share price was $3.51, and it changed around $0.08 or 2.33% from the last close, which brings the market valuation of the company to $237.24M. CATX at last check was trading at a discount to its 52-week high of $19.05, offering almost -442.74% off that amount. The share price’s 52-week low was $2.70, which indicates that the recent value has risen by an impressive 23.08% since then. We note from Perspective Therapeutics Inc’s average daily trading volume that its 10-day average is 1.22 million shares, with the 3-month average coming to 1.56 million.
Perspective Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.18. If we narrow it down even further, the data shows that 0 out of 10 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 1 recommended CATX as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. Perspective Therapeutics Inc is expected to report earnings per share of -0.26 for the current quarter.
Perspective Therapeutics Inc (AMEX:CATX) trade information
Instantly CATX has been showing a green trend so far today with a performance of 2.33% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 3.53 on recent trading dayincreased the stock’s daily price by 0.57%. The company’s shares are currently up 10.03% year-to-date, but still up 3.24% over the last five days. On the other hand, Perspective Therapeutics Inc (AMEX:CATX) is 14.33% up in the 30-day period. We can see from the shorts that 8.93 million shares have been sold at a short interest cover period of 6.53 day(s).
The consensus price target as assigned by Wall Street analysts is $21.5, which translates to bulls needing to increase their stock price by 83.67% from its current value. Analyst projections state that CATX is forecast to be at a low of $20 and a high of $24.
Perspective Therapeutics Inc (CATX) estimates and forecasts
Perspective Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -72.23 percent over the past six months and at a 37.14% annual growth rate that is well above the industry average of 16.50%. The year-over-year growth rate is expected to be -4.40%, down from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of 286.4k in revenue for the current quarter. 4 analysts expect Perspective Therapeutics Inc to make 151.33k in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were -4.9M and 325k respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 105.84%. Forecasts for the next quarter put sales growth at -53.44%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -7.69%.
CATX Dividends
Perspective Therapeutics Inc’s next quarterly earnings report is expected to be released in February.
Perspective Therapeutics Inc (AMEX:CATX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 20.46% of Perspective Therapeutics Inc shares, and 81.53% of them are in the hands of institutional investors. The stock currently has a share float of 102.50%.
Vanguard Total Stock Market Index Fund and Fidelity Advisor Biotechnology Fund were the top two Mutual Funds as of Sep 30, 2024 . The former held 1.69 shares worth $5.99 million, making up 2.50% of all outstanding shares. On the other hand, Fidelity Advisor Biotechnology Fund held roughly 1.6 shares worth around $5.67 million, which represents about 2.37% of the total shares outstanding.
